Jane Street Group LLC Lowers Stock Position in CareDx, Inc (NASDAQ:CDNA)

Jane Street Group LLC reduced its position in CareDx, Inc (NASDAQ:CDNA - Free Report) by 19.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 123,729 shares of the company's stock after selling 29,167 shares during the quarter. Jane Street Group LLC owned 0.23% of CareDx worth $2,649,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Thompson Davis & CO. Inc. boosted its holdings in CareDx by 6.3% during the 4th quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company's stock valued at $344,000 after acquiring an additional 950 shares during the period. Hsbc Holdings PLC boosted its stake in shares of CareDx by 6.9% during the fourth quarter. Hsbc Holdings PLC now owns 17,131 shares of the company's stock valued at $365,000 after purchasing an additional 1,109 shares during the period. Legal & General Group Plc grew its holdings in shares of CareDx by 1.3% in the fourth quarter. Legal & General Group Plc now owns 89,751 shares of the company's stock worth $1,922,000 after purchasing an additional 1,118 shares during the last quarter. Sterling Capital Management LLC increased its stake in shares of CareDx by 771.2% in the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock worth $27,000 after buying an additional 1,126 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in CareDx by 6.5% during the 4th quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock valued at $406,000 after buying an additional 1,151 shares during the last quarter.

CareDx Stock Performance

Shares of CareDx stock traded down $0.48 during trading on Tuesday, hitting $17.23. The company's stock had a trading volume of 58,941 shares, compared to its average volume of 885,621. CareDx, Inc has a 52 week low of $12.90 and a 52 week high of $34.84. The company has a fifty day simple moving average of $17.60 and a two-hundred day simple moving average of $20.88. The company has a market capitalization of $959.11 million, a PE ratio of -6.35 and a beta of 2.27.

CareDx (NASDAQ:CDNA - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.03. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The firm had revenue of $84.69 million during the quarter, compared to analyst estimates of $84.56 million. During the same period last year, the business earned ($0.03) earnings per share. The business's revenue was up 17.6% on a year-over-year basis. As a group, analysts predict that CareDx, Inc will post -0.9 EPS for the current year.

Insider Transactions at CareDx

In related news, Director Christine Cournoyer sold 29,136 shares of the stock in a transaction on Monday, May 12th. The stock was sold at an average price of $15.96, for a total transaction of $465,010.56. Following the sale, the director now directly owns 37,045 shares of the company's stock, valued at $591,238.20. This trade represents a 44.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Peter Maag sold 13,281 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $17.23, for a total transaction of $228,831.63. Following the completion of the sale, the director now owns 316,743 shares in the company, valued at $5,457,481.89. This represents a 4.02% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 59,382 shares of company stock valued at $934,509. Insiders own 4.90% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. HC Wainwright restated a "neutral" rating and issued a $25.00 price objective on shares of CareDx in a research report on Monday, May 5th. StockNews.com downgraded CareDx from a "buy" rating to a "hold" rating in a report on Monday, May 5th. The Goldman Sachs Group dropped their target price on shares of CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Finally, Stephens reaffirmed an "overweight" rating and set a $40.00 target price on shares of CareDx in a research note on Monday, May 5th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $30.33.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.